Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Current Leases (2019 - 2026)

Avanos Medical's Current Leases history spans 7 years, with the latest figure at $8.2 million for Q4 2025.

  • On a quarterly basis, Current Leases fell 24.77% to $8.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.2 million, a 24.77% decrease, with the full-year FY2025 number at $8.2 million, down 24.77% from a year prior.
  • Current Leases hit $8.2 million in Q4 2025 for Avanos Medical, down from $9.5 million in the prior quarter.
  • Over the last five years, Current Leases for AVNS hit a ceiling of $15.1 million in Q1 2021 and a floor of $8.2 million in Q4 2025.
  • Historically, Current Leases has averaged $12.6 million across 5 years, with a median of $13.1 million in 2022.
  • Biggest five-year swings in Current Leases: rose 7.87% in 2024 and later plummeted 30.66% in 2025.
  • Tracing AVNS's Current Leases over 5 years: stood at $14.7 million in 2021, then decreased by 18.37% to $12.0 million in 2022, then grew by 6.67% to $12.8 million in 2023, then dropped by 14.84% to $10.9 million in 2024, then fell by 24.77% to $8.2 million in 2025.
  • Business Quant data shows Current Leases for AVNS at $8.2 million in Q4 2025, $9.5 million in Q3 2025, and $10.4 million in Q2 2025.